Page 140 - 2018_09-Mondo

S.J. Lee et al.
respondent burden while delivering robust, reliable QOL scores. Finally, all scores are standardized for comparisons, and there are general population normative values for all the scales. Algorithms exist to convert between other commonly utilized and validated instruments using con- version factors.26
We recognize a number of caveats regarding our study. This is a single institution, cross-sectional study and
Table 4. Self-reported health status.1
Organs still Type of chronic GvHD affected by Never Resolved Mild
chronicGvHD n % n % n % n
reflects the patient population and practices of one institu- tion. The response rate was 45%, which is lower than ideal but adequate to conduct analyses given the sample size. This is a late survivorship population with a mean of 13.8 years since HCT, and only 25 participants reported severe chronic GvHD. We hypothesize that chronic GvHD may have already exacted a toll so that those with the highest morbidity died prior to the survey or did not
Moderate Severe
% n %
P-value2 <0.0001
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
0.27
0.03 <0.0001
0.02 <0.0001
<0.0001
<0.0001
<0.0001
0.09 0.11
0.007
0.002
<0.0001
<0.0001
<0.0001
<0.0001
Skin 5
Mouth 3 Eyes 3 Intestine 4 Esophagus 0 Liver 0 Lungs 0 Joints 2 Genitals 0
Comorbidities
Pulmonarydisease 19
Avascularnecrosis 19
Osteopenia/ 107 osteoporosis
Diabetes 41
Adrenal 5 insufficiency
Current medications
Prednisone 14
Other immuno- 23
suppressive drugs
Prophylactic 47 antimicrobials
Anti-hypertensives 115
Treatment of 20
arrhythmias Anxiolytics 45
Antidepressants 46
Prevention or 47 treatment of
osteoporosis
Prescription pain 35 medication
Work/school status
Work, school or 308 homemaking full
or part time, retired by choice
Not working, not 56 in school, unemployed, or retired due to health
KPS(median,IQR) 100
1.3 6 2.1
0.8 4 1.4 0.8 6 2.1 1.1 2 0.7 -- 0 -- -- 1 0.4 -- 0 -- 0.5 2 0.7 -- 1 0.4
5.1 25 9.2
5.2 33 12.4 29.2 104 39.0
10.9 39 14.2 1.4 9 3.4
3.7 9 3.3
6.1 16 5.8
12.6 29 10.6
30.7 112 40.3 5.3 15 5.5
12.0 42 15.3 12.2 43 15.6 12.5 40 14.7
9.4 29 10.5
84.6 239 87.9
15.4 33 12.1
(90-100) 100 (90-100)
123 47.9
128 49.8 115 44.7 34 13.2 21 8.2
77 70.0 14
63 57.3 10 71 64.5 15 24 21.8 3 7 6.4 5
56.0
40.0 60.0 12.0 20.0 12.0 32.0 24.0 8.0
4.0
13.6 50.0
16.7 --
68.0
56.0
72.0
36.0 16.7
25.0 32.0 29.2
37.5
24 9.3 5 4.5 3
28 10.9 30 11.7 16 6.2
18 7.1
24 9.7 107 44.8
27 10.8 18 7.5
90 35.7
91 37.0
127 50.6
85 33.6 22 8.7
47 19.0 48 19.0 64 25.7
50 19.8
184 73.3
67 26.7
90 (80-100)
22 20.0 8 32 29.1 6 11 10.0 2
10 9.2 1
10 9.9 3 51 49.0 12
24 22.4 4 12 11.6 0
64 58.7 17
55 53.9 14
71 66.4 18
44 40.4 9 9 8.4 4
27 25.2 6 27 25.2 8 31 28.7 7
43 40.2 9
63 60.6 17 70.8
41 39.4 7 29.2
80 (70-90) 70
(70-90)
1Based on endorsement of each item. Missing responses and “don’t know” were excluded. 2Karnofsky performance score (KPS) comparison based on the Wilcoxon rank sum test.All other factors were compared based on chi-squared or Fisher exact tests for patients across all five categories.
1540
haematologica | 2018; 103(9)